These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 25644429)

  • 1. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
    Chakraborty S; Yadav L; Aggarwal D
    Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
    Beloica S; Cvijić S; Bogataj M; Parojčić J
    Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
    Kambayashi A; Dressman JB
    Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling.
    Li J; Chai H; Li Y; Chai X; Zhao Y; Zhao Y; Tao T; Xiang X
    PLoS One; 2016; 11(8):e0160260. PubMed ID: 27479702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
    Rasool BK; Fahmy SA; Galeel OW
    Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.